Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation... (han dacarbazine that are currently used ...)

Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium

Date:11/8/2007

han dacarbazine that are currently used for treatment of patients with advanced melanoma," commented Dr. Pavlick. "Genasense has already demonstrated significant benefit when combined with dacarbazine, and we are pleased to be participating in the confirmatory AGENDA trial. The early data from our new 3-drug study are highly encouraging, and we hope to extend these observations by incorporating the brief IV infusion schedule for Genasense that has recently been developed. This new regimen may offer an active, safe, and convenient treatment for patients with this devastating disease."

The activity of this triple drug combination is supported by preclinical data that were presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. These data can be accessed at: http://www.genta.com/index.php?option=com_content&task=view&id=60&Itemid=73 &CI D=43&SHID=&COID

Results from the previous randomized trial of Genasense plus dacarbazine can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1

About AGENDA: A randomized Phase 3 trial of Genasense in advanced melanoma

The AGENDA This trial seeks to confirm the effectiveness and safety of the Genasense/dacarbazine combination in patients who had the greatest benefit in a preceding randomized trial. AGENDA will enroll approximately 300 patients at sites in North America, Europe and Australia using a biomarker that has been confirmed as a powerful indicator of outcome. More information about AGENDA can be accessed at: http://www.genta.com/index.php?option=com_content&task=view&id=38&Itemid=55

About Genta

Genta Incorporated is a biopharmaceutical company
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes

Post Your Comments:

Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation...(han dacarbazine that are currently used ...)